Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Tan

Showing results (571-580 of 640) with videos related to

Pageof 64
Sort By:
Nano Letters|December 19, 2017
Mo-Terminated Edge Reconstructions in Nanoporous Molybdenum Disulfide FilmXiaoxu Zhao, Deyi Fu, Zijing Ding, et al.
JAMA Oncology|May 30, 2020
FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers: A Phase 2 Nonrandomized Clinical TrialHaeseong Park, Ramon U Jin, Andrea Wang-Gillam, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|March 18, 2026
Northern Hemisphere 2025/26 influenza vaccine effectiveness during months with influenza A(H3N2) subclade K predominance- Suzhou, Eastern ChinaPengwei Cui, Suizan Zhou, Anna N Chard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 10, 2021
Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II StudyAntoinette R Tan, Gail S Wright, Anu R Thummala, et al.
International Journal of Cardiology|December 3, 2014
One-year outcome following biological or mechanical valve replacement for infective endocarditisF Delahaye, V H Chu, J Altclas, et al.
Cancer Chemotherapy and Pharmacology|February 17, 2020
Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumorsAnthony W Tolcher, Razelle Kurzrock, Vincente Valero, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 22, 2018
Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast CancerHope S Rugo, Jean-Pierre Delord, Seock-Ah Im, et al.
The Lancet. Oncology|October 3, 2019
Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trialAntoinette R Tan, Gail S Wright, Anu R Thummala, et al.
The American Journal of Surgical Pathology|December 6, 2003
Analysis of protein expression and gene mutation of c-kit in colorectal neuroendocrine carcinomasOlaronke Akintola-Ogunremi, John D Pfeifer, Benjamin R Tan, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 29, 2019
Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell LymphomaStefan K Barta, Jasmine Zain, Alexander W MacFarlane, et al.
Pageof 64

Showing results (571-580 of 640) with videos related to

Sort By:
Pageof 64
Nano Letters|December 19, 2017
Mo-Terminated Edge Reconstructions in Nanoporous Molybdenum Disulfide FilmXiaoxu Zhao, Deyi Fu, Zijing Ding, et al.
JAMA Oncology|May 30, 2020
FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers: A Phase 2 Nonrandomized Clinical TrialHaeseong Park, Ramon U Jin, Andrea Wang-Gillam, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|March 18, 2026
Northern Hemisphere 2025/26 influenza vaccine effectiveness during months with influenza A(H3N2) subclade K predominance- Suzhou, Eastern ChinaPengwei Cui, Suizan Zhou, Anna N Chard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 10, 2021
Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II StudyAntoinette R Tan, Gail S Wright, Anu R Thummala, et al.
International Journal of Cardiology|December 3, 2014
One-year outcome following biological or mechanical valve replacement for infective endocarditisF Delahaye, V H Chu, J Altclas, et al.
Cancer Chemotherapy and Pharmacology|February 17, 2020
Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumorsAnthony W Tolcher, Razelle Kurzrock, Vincente Valero, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 22, 2018
Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast CancerHope S Rugo, Jean-Pierre Delord, Seock-Ah Im, et al.
The Lancet. Oncology|October 3, 2019
Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trialAntoinette R Tan, Gail S Wright, Anu R Thummala, et al.
The American Journal of Surgical Pathology|December 6, 2003
Analysis of protein expression and gene mutation of c-kit in colorectal neuroendocrine carcinomasOlaronke Akintola-Ogunremi, John D Pfeifer, Benjamin R Tan, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 29, 2019
Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell LymphomaStefan K Barta, Jasmine Zain, Alexander W MacFarlane, et al.
Pageof 64